Recruiting Heart Attack Studies in Stanford
A Long-term Extension Study of PCI-32765 (Ibrutinib)
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolle...
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (I...
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the t...
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate re...
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Asso...
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
This 3-part, Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the selected dose of mRNA-3927 ...
Avexitide for Treatment of Post-Bariatric Hypoglycemia
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess...
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated....
About Heart Attack Clinical Trials in Stanford
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 8 heart attack clinical trials recruiting participants in Stanford, CA. These studies are seeking a combined 2,717 participants. Research is being sponsored by Janssen Research & Development, LLC, Daiichi Sankyo, Celgene and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in Stanford — FAQ
Are there heart attack clinical trials in Stanford?
Yes, there are 8 heart attack clinical trials currently recruiting in Stanford, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Stanford?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Stanford research site will contact you about next steps.
Are clinical trials in Stanford free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Stanford studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 8 active trials in Stanford are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov